secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-149624
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyntra Bio receives Nasdaq delisting notice for failing $50M assets/revenue rule
--------------------------------------------------------------------------------

- Received Nasdaq letter on April 2, 2026, for non-compliance with Listing Rule 5450(b)(3)(A) regarding $50M total assets and revenue.
- Non-compliance due to FibroGen International revenue reclassified as discontinued operations in 2024-2025.
- Company has 45 days (by May 18, 2026) to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.
- Company may consider transferring to Nasdaq Capital Market as alternative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/0001193125-26-149624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/kynb-20260402.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-149624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer